Welcome to our dedicated page for AGILE THERAPEUTICS news (Ticker: AGRX), a resource for investors and traders seeking the latest updates and insights on AGILE THERAPEUTICS stock.
Agile Therapeutics Inc. (AGRX) is an innovative women's healthcare company focused on developing non-daily contraceptive solutions through its proprietary transdermal technology. This page serves as the definitive source for verified news and official announcements related to product developments, regulatory milestones, and corporate updates.
Investors and healthcare professionals will find comprehensive coverage of Twirla® contraceptive patch updates, financial performance reports, and strategic partnership announcements. Our curated collection ensures timely access to earnings releases, clinical trial progress, and manufacturing updates while maintaining strict adherence to factual reporting standards.
Key information categories include FDA regulatory communications, research advancements in transdermal drug delivery, and market expansion initiatives. All content is rigorously verified to provide reliable insights into the company's position within the women's health sector.
For those monitoring AGRX's progress in contraceptive innovation, we recommend bookmarking this page and checking regularly for essential updates. Our commitment to neutral, accurate reporting makes this your trusted resource for understanding Agile Therapeutics' role in advancing patient-centric healthcare solutions.
Agile Therapeutics (Nasdaq: AGRX) has appointed Josephine Torrente to its board of directors, effective October 7, 2021. As a Class II director, she will serve on the Science and Technology and Nominating and Corporate Governance Committees. Torrente, who has over 30 years of experience in the pharmaceutical industry, brings regulatory expertise and strategic insights that Agile anticipates will enhance its growth trajectory. Her previous roles include Executive VP at Sprout Pharmaceuticals and extensive work at a law firm specializing in FDA matters.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced the pricing of its public offering of 26,666,648 shares of common stock and warrants for 13,333,324 shares at $0.85 per share. The expected gross proceeds are approximately $22.67 million, before expenses. The warrants are exercisable immediately at the same price and expire in five years. The offering, led by Oppenheimer & Co., is set to close around October 13, 2021, pending customary conditions. Agile continues to focus on women's healthcare, notably through its contraceptive product, Twirla.
Agile Therapeutics (Nasdaq: AGRX) announced plans for an underwritten public offering of its common stock and warrants to purchase its common stock. All shares offered will be sold by the company, with the offering dependent on market conditions. Oppenheimer & Co. Inc. is the sole book-running manager for the offering, which will be conducted under Agile's effective shelf registration statement filed with the SEC. Potential investors are encouraged to review the preliminary prospectus supplement and accompanying prospectus for detailed information.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced that the California Medicaid Program, Medi-Cal, has officially added Twirla to its preferred drug list as of October 1, 2021. This inclusion applies to approximately 15 million beneficiaries in California, initially affecting those under fee-for-service plans and expanding to other beneficiaries by January 1, 2022. CEO Al Altomari emphasized the importance of broadening access to contraceptive options and highlighted Twirla as a significant choice for women seeking low-dose estrogen contraceptives.
Agile Therapeutics, Inc. (Nasdaq: AGRX) announced a partnership with U.S. Women’s Soccer star Carli Lloyd on September 28, 2021. This collaboration aims to raise awareness about women’s health issues and promote Agile's mission in women's healthcare. Lloyd, who will play her final match for the U.S. Women’s National Team on October 26, is passionate about empowering women in their healthcare choices. Agile's first product, the contraceptive patch Twirla, was FDA-approved in February 2020, and the company has four additional contraceptive products in development.
Agile Therapeutics (Nasdaq: AGRX) announced participation in several virtual investor conferences in September 2021. Key events include the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 20, and the Cantor Fitzgerald Virtual Global Healthcare Conference from September 27-30. Presentations will feature live webcasts available on their Investor Relations website. Agile is focused on women's healthcare with products like the transdermal contraceptive, Twirla.
Agile Therapeutics (Nasdaq: AGRX) has partnered with Pandia Health to launch the first telehealth platform for the Twirla® birth control patch. This collaboration aims to enhance women's access to contraceptive care through online prescriptions and free delivery. Set to phase in Twirla availability in H2 2021, this partnership aligns with the growing trend of telehealth in contraceptive services, especially post-COVID-19. Agile emphasizes its commitment to women's health in this initiative.
Agile Therapeutics (Nasdaq: AGRX) reported significant growth in the second quarter of 2021, with total prescriptions for Twirla increasing by 171% to 5,027. New prescriptions also rose by 103%, driven by a growing number of prescribers exceeding 2,087. The company achieved $1.2 million in net product sales but recorded a net loss of $17.6 million for the quarter. Agile has $31.1 million in cash and options for additional capital through loans and an at-the-market facility. A conference call is scheduled for July 26, 2021.
Agile Therapeutics (Nasdaq: AGRX) will release its second quarter 2021 financial results on July 26, 2021, post-market. A live conference call will occur at 4:30 p.m. EDT, featuring dial-in options for both domestic and international investors. Interested parties can access the live stream and archived webcast through the company's website. Agile Therapeutics focuses on women's healthcare, offering innovative contraceptive solutions, including the non-daily prescription contraceptive, Twirla, utilizing their proprietary Skinfusion® technology.
Agile Therapeutics, a women’s healthcare company, will participate virtually in the William Blair 41st Annual Growth Stock Conference on June 1, 2021, at 10:20 a.m. ET. CEO Al Altomari will lead a fireside chat, which can be accessed live through the Agile Therapeutics website. The webcast will be available for 30 days post-event. Agile Therapeutics is focused on addressing women's healthcare needs, with its primary product being Twirla®, a non-daily transdermal contraceptive system designed for ease of use.
FAQ
What is the current stock price of AGILE THERAPEUTICS (AGRX)?
What is the market cap of AGILE THERAPEUTICS (AGRX)?
